SERB Acquires Y-mAbs Therapeutics in $412M All-Cash Deal

Published on LinkedIn via Spencer Knight

SERB Pharmaceuticals will acquire Y-mAbs Therapeutics for $412 million, marking a strategic expansion into pediatric oncology and radiolabeled immunotherapies. The deal includes DANYELZA, the first FDA-approved treatment for relapsed/refractory high-risk neuroblastoma, known for its outpatient use and accessibility. SERB will also gain early-stage SADA platform assets targeting GD2 and CD38. The acquisition adds to SERB’s rare oncology portfolio alongside Voraxaze and Xermelo.

Read the full article on LinkedIn:

👉 SERB to Acquire Y-mAbs Therapeutics for $412M

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.